Nolato ABFRA:NBF +6.95%82 Net Margin % is 7.68% as of Mar. 2026, which is 8% below its 10-year median of 8.36. GuruFocus rates FRA:NBF with a GF Score™ of 82/100 and a GF Value™ of €5.00 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Nolato AB ranks better than 67.56% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Nolato AB's Net Income for the
three
months ended in Mar. 2026 was €16.8 Mil. Nolato AB's Revenue for the
three
months ended in Mar. 2026 was €218.8 Mil. Therefore, Nolato AB's net margin for the quarter that ended in Mar. 2026 was 7.68%.
The historical rank and industry rank for Nolato AB's Net Margin % or its related term are showing as below:
FRA:NBF'
s Net Margin % Range Over the Past 10 Years
Min: 4.56 Med: 8.36 Max: 9.99
Current: 8.1
FRA:NBF's Net Margin % is ranked better than 67.56% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs FRA:NBF: 8.10
Nolato AB (FRA:NBF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Nolato AB Net Margin % Related Terms
Nolato AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Nolato AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nolato AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nolato AB Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nolato AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Nolato AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nolato AB (FRA:NBF) has a Net Margin % of 7.68% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Nolato AB and its competitors. This is near median its historical median of 8.36. Over the past decade, Nolato AB's Net Margin % has ranged from 4.56 to 9.99. According to the industry distribution chart, Nolato AB ranks #265 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 32.4%.
Is Nolato AB's Net Margin % too high?
Nolato AB's current Net Margin % of 7.68% is near median its 10-year median of 8.36. Over the past 10 years, this metric has ranged from a low of 4.56 to a high of 9.99. The Medical Devices & Instruments industry median Net Margin % is 2.09. Nolato AB's value of 7.68% is 267.5% above this industry median. Based on the distribution chart, Nolato AB ranks #265 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nolato AB has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nolato AB's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nolato AB ranks #265 out of 817 companies for Net Margin %. This puts Nolato AB in the upper half of its industry. The industry median Net Margin % is 2.09. Nolato AB's value of 7.68% is 267.5% above this benchmark. Historically, Nolato AB's own Net Margin % has ranged from 4.56 to 9.99 over the past decade. While the company's 10-year median is 8.36 vs. the industry median of 2.09, Nolato AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nolato AB's current Net Margin % of 7.68% is 267.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Nolato AB and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nolato AB's current Net Margin % is 7.68%, which is near median its own 10-year median of 8.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nolato AB stock overvalued right now?
Based on GuruFocus' analysis, Nolato AB (FRA:NBF) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.00, compared to a current price of €4.47 — trading 10.7% below its estimated fair value. The current Net Margin % is 7.68%, which is near median its 10-year median of 8.36 and 267.5% above the Medical Devices & Instruments industry median of 2.09. Nolato AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Nolato AB (FRA:NBF), the current Net Margin % is 7.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nolato AB (FRA:NBF) Overvalued in 2026?
Based on GuruFocus' analysis, Nolato AB stock appears to be undervalued.
The current stock price of €4.47 is trading 10.7% below its estimated GF Value™ of €5.00.
GuruFocus considers Nolato AB to be Modestly Undervalued.
Key valuation signals for FRA:NBF:
Net Margin %: 7.68% (near median its 10-year median of 8.36)
GF Value™: €5.00 vs. price of €4.47 (10.7% below fair value)
Industry Position: 267.5% above the Medical Devices & Instruments median (#265 of 817)
No single metric tells the full story. See the FRA:NBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nolato AB is a Swedish company that develops and manufactures plastic, silicone, and thermoplastic elastomer products. The firm's operations are organized into two segments: Medical Solutions and Engineered Solutions. The company generates the majority of its revenue from the Medical Solutions segment, which is engaged in the development and manufacture of complex product systems and components for medical devices, the pharmaceutical industry, and diagnostics. The Engineered Solutions design, development, industrialization, and manufacture of subsystems and ready-packaged products for a range of industries, including offerings within EMC and thermal solutions. Geographically, the firm generates key revenue from the Rest of Europe and the United States.
82GF Score
Get the complete analysis for FRA:NBF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NBF has been successfully added to your 
